DNP Green Technology bags green chemistry pioneer Bioamber S.A.S


Pomacle/Minneapolis – US company DNP Green Technology and French Agroindustrie Recherches et Developpements (ARD) have restructured their successful joint venture Bioamber S.A.S, the world’s first company manufacturing the chemical building block succinic acid using a biotechnological CO2-consuming process from renewable instead petrochemical resources. According to the companies, DNP Green Technology acquired 100% of the shares in Bioamber, and ARD became a shareholder in DNP Green Technology, which will be renamed Bioamber Inc. „This was the right moment to restructure our joint venture“, said Jean‐Francois Huc, CEO of DNP Green Technology. „Our collaboration has evolved into a business which demands rapid commercialization of bio-based succinic acid, in order to take full advantage of our position as first to market. Both partners felt that this could best be achieved through DNP Green. According to both companies, Bioamber Inc will take over full responsibility of commercialization. ARD focus will be on process optimization in the plant and the scale up of a next-generation organism producing succinic acid.
In January, Bioamber had started a bio-succinic acid plant with an annual production capacity of 2,000 metric tons in Pomacle near Reims. According to Bioamber’s former managing director, Patrick Piot, Bioamber is targeting a EUR210m world market of approximately 30,000 metric tonnes per year that is expected to grow rapidly. Simple chemical conversion to 1.4 butane-diol opens up another market opportunity of 1.3 million tonnes per annum. Bioamber does not plan to build larger plants. Instead, the company’s business model is to outlicense the technology to industrial partners.
Several chemistry firms, including Mitsubishi Chemical Corp/Ajinomoto, Royal DSM/Roquette, and BASF/Purac, have also established fermentation processes to produce succinic acid with the help of metabolically engineered bacteria. While Mitsubishi and DSM are yet to produce on a pilot scale, German world market leaders BASF kicked off 2009 a 4,000 tonne/year commercial production plant with its partner Purac near Barcelona but the start of industrial production has been delayed, according to the companies.




Stockholm/Suresnes - Swedish BioInvent International AB and French Laboratoires Servier are working together on an oncology target. Under the terms of the agreement, Servier will engage BioInvent to screen its proprietary library...



Romainville – Cellectis SA has completed its acquisition of Cellartis AB, which provides stem cell-based in vitro R&D tools, in a cash and stock deal valued at €29.1m (US$39.9m). Cellartis shareholders received 1.9 million...



Paris – One of the biggest European biotech deals of 2011 is now sealed. As announced in September, the shareholders of French genome engineering specialist Cellectis approved the takeover of Swedish Cellartis, the European...



Paris - Sanofi and MS patients can breathe a sigh of relief. At an MS congress in Amsterdam, the company presented impressive results of a phase III trial comparing alemtuzumab with subcutaneous Rebif interferon beta-1a in 581...



Paris/Boulder – French drugmaker Servier has secured the rights for two miroRNA drug candidates from US-biotech MiRagen. Both companies clinched a partnership agreement under which Servier would fund the research, development and...



Paris/Hyderabad – Sanofi Aventis believes in India. The pharmaceutical company announced the opening a state-of-the-art vaccine manufacturing facility, believed to be Asia's biggest, in March 2012. In the coming years Sanofi will...



Paris – Nanobiotix S.A. is entering the clinical stage with its NanoXray nano­particle therapy, which aims to increase the efficacy of radiotherapy without increasing dosage. In mid-September, the French nano­medicine company...

Sweden, FranceFrance


Paris – For €16.4m in cash and roughly €12m in shares, French genome engineering specialist Cellectis has taken over Swedish Cellartis. Cellartis is the European leader in stem cell-derived cardiomyocytes and hepatocytes. With 62...

Germany, FranceFrance


Luxembourg - Disorientation reigns in green biotechnology in Europe. Two decisions by the European Court of Justice regarding genetically modified crops point in different directions. On Thursday the judges left the opponents of...

Displaying results 11 to 20 out of 268

< Previous 11-20 Next >

© 2007-2016 BIOCOM


Current issue

All issues

Product of the week


Stock list

All quotes


  • NEWRON (CH)22.65 CHF9.69%
  • VERNALIS (UK)45.00 GBP4.65%
  • KARO BIO (S)40.00 SEK4.44%


  • PROTHENA PLC (IE)50.02 USD-7.70%
  • BIONOR PHARMA (N)0.44 NOK-6.38%


  • DIAMYD MEDICAL -B- (S)7.25 SEK68.6%
  • KARO BIO (S)40.00 SEK28.6%
  • MOLMED (I)0.42 EUR27.3%


  • BIONOR PHARMA (N)0.44 NOK-27.9%
  • NOVOZYMES (DK)284.40 DKK-14.3%
  • RENEURON (UK)2.75 GBP-12.4%


  • NICOX (F)10.26 EUR442.9%
  • SAREUM HOLDINGS (UK)0.74 GBP252.4%
  • GENMAB (DK)1126.00 DKK100.9%


  • BB BIOTECH (D)46.74 EUR-81.5%
  • EVOCUTIS (UK)0.04 GBP-80.0%
  • CIRCASSIA LIMITED (L)94.70 GBP-70.9%

No liability assumed, Date: 25.08.2016


All Events